CIMA LABS INC. has signed a second agreement with Schwarz Pharma for a controlled release formulation of its DuraSolv dosage form of an undisclosed prescription product. The Agreement is expected to add approximately $ 1.3 million in product development fees and licensing revenue during the product development phase, which is estimated at two years. “This Read more about Cima And Schwarz Sign Development And Supply Agreement[…]